AVIR Stock Analysis: Buy, Sell, or Hold?
AVIR - Atea Pharmaceuticals, Inc. Common Stock
$5.43
0.07 (1.31%)
▲
5d:
+6.05%
30d:
+14.32%
90d:
+28.07%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When AVIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AVIR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AVIR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AVIR is currently trading at $5.43, which is considered extended relative to its 30-day fair value range of $4.67 to $5.21.
Technical Outlook: Technically, AVIR is in a downtrend. Immediate support is located at $4.92, while resistance sits at $5.64.
Market Sentiment: AVIR scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.42 (+73.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AVIR is in a downtrend. Immediate support is located at $4.92, while resistance sits at $5.64.
Market Sentiment: AVIR scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.42 (+73.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.67 -
$5.21
Company Quality Score
30/100
(SELL)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
35.4%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 73.4% below Wall St target ($9.42)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.67 -
$5.21
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.96
(17.8%)
Support & Resistance Levels
Support Level
$4.92
Resistance Level
$5.64
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.67
Wall Street Target
$9.42
(+73.4%)
Revenue Growth (YoY)
295.2%
Earnings Growth (YoY)
264.1%
Share & Embed Analysis
Last updated: August 23, 2026 11:25 AM ET
Data refreshes hourly during market hours. Next update: 12:25 PM
Data refreshes hourly during market hours. Next update: 12:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |